TP53 mutations disrupting the loop 2 and loop 3 domains of the protein have been shown to predict poor survival in breast cancer (Borresen et al, 1995) and colorectal cancer (Borresen-Dale et al, 1998). Here, TP53 is linked to breast carcinoma.